| Literature DB >> 30127623 |
Hong-Hao Li1, Lu-Nan Qi1,2,3, Liang Ma1,2, Zu-Shun Chen1, Bang-De Xiang1,2,3, Le-Qun Li1,2,3.
Abstract
OBJECTIVE: This study aimed to explore the relationship between KI-67 positive cellular index and recurrence-free survival (RFS) in Barcelona Clinic Liver Cancer (BCLC) stage A and B hepatocellular carcinoma (HCC) patients, particularly those with microvascular invasion (MVI).Entities:
Keywords: BCLC stage A and B; KI-67; hepatectomy; hepatocellular carcinoma; microvascular invasion; prognosis
Year: 2018 PMID: 30127623 PMCID: PMC6091480 DOI: 10.2147/OTT.S165244
Source DB: PubMed Journal: Onco Targets Ther ISSN: 1178-6930 Impact factor: 4.147
Clinical characteristics
| Age (years), mean ± SD (range) | 48.4±0.58 (29–79) |
| Sex | |
| Male, n (%) | 284 (85.3%) |
| Female, n (%) | 49 (14.7%) |
| HBsAg | |
| Positive, n (%) | 288 (86.4%) |
| Negative, n (%) | 45 (13.6%) |
| HBV DNA | |
| >500 copies/mL, n (%) | 232 (69.7%) |
| ≤500 copies/mL, n (%) | 101 (30.3%) |
| AFP | |
| >400 ng/mL, n (%) | 165 (49.5%) |
| ≤400 ng/mL, n (%) | 168 (50.5%) |
| Tumor size | |
| >5 cm, n (%) | 195 (58.6%) |
| ≤5 cm, n (%) | 138 (42.4%) |
| Edmondson stage | |
| Low, n (%) | 223 (67.0%) |
| High, n (%) | 110 (33.0%) |
| Node number | |
| Single, n (%) | 235 (70.6%) |
| Multiple, n (%) | 98 (29.4%) |
| Capsule | |
| Complete, n (%) | 249 (74.8%) |
| Absent, n (%) | 84 (25.2%) |
| Cirrhosis degree | |
| Low, n (%) | 222 (66.7%) |
| High, n (%) | 111 (33.3%) |
| MVI | |
| Positivity, n (%) | 191 (57.4%) |
| Negativity, n (%) | 142 (42.6%) |
| KI-67 positive cellular index | |
| High, n (%) | 137 (41.1%) |
| Low, n (%) | 196 (58.9%) |
Abbreviations: AFP, alpha-fetoprotein; HBsAg, serum hepatitis B surface antigen; HBV DNA, hepatitis B virus DNA levels; MVI, microvascular invasion.
Figure 1Pathologically, primary cellular carcinoma of the liver (H&E, ×100): (A) proportion of positive cellular index ≤35% and (B) proportion of positive cellular index >35%. (C) Representative image showing significant differences in KI-67 positive cellular index between HCC tissues and adjacent non-tumor tissues.
Note: KI-67 positive cellular index was defined as the presence of nuclear staining.
Abbreviation: HCC, hepatocellular carcinoma.
Figure 2Comparison of the recurrence-free survival curves between high KI-67 group and low KI-67 group.
Notes: Results are from Kaplan–Meier analysis. P<0.05 was considered to be statistically significant.
Factors associated with postoperative recurrence in HCC
| Variables | Univariate analysis
| Multivariate Cox analysis
| |
|---|---|---|---|
| HR (95% CI) | |||
| Age (years) | 0.011 | 0.90 (0.68–1.18) | 0.44 |
| >48 | |||
| ≤48 | |||
| Sex | 0.916 | ||
| Male | |||
| Female | |||
| HBsAg | 0.002 | 1.66 (0.98–2.80) | 0.60 |
| Positive | |||
| Negative | |||
| Edmondson | 0.861 | ||
| Low stage | |||
| High stage | |||
| AFP (ng/mL) | 0.023 | 1.46 (1.11–1.92) | 0.007 |
| >400 | |||
| ≤400 | |||
| Tumor size (cm) | 0.023 | 1.37 (1.03–1.83) | 0.031 |
| >5 | |||
| ≤5 | |||
| HBV DNA (copies/mL) | 0.045 | 0.92 (0.65–1.32) | 0.67 |
| >500 | |||
| ≤500 | |||
| Node number | <0.001 | 1.99 (1.50–2.66) | <0.001 |
| Single | |||
| Multiple | |||
| Capsule | <0.001 | 2.89 (2.15–3.90) | <0.001 |
| Absent | |||
| Complete | |||
| Cirrhosis | 0.207 | ||
| Moderate or high | |||
| Low | |||
| MVI | <0.001 | 1.80 (1.33–2.42) | <0.001 |
| Positivity | |||
| Negativity | |||
| KI-67 positive cellular index | <0.001 | 2.13 (1.62–2.80) | <0.001 |
| High | |||
| Low | |||
| Surgical margin (cm) | 0.512 | ||
| <1 | |||
| >1 | |||
Abbreviations: AFP, alpha-fetoprotein; HBsAg, serum hepatitis B surface antigen; HBV DNA, hepatitis B virus DNA levels; HCC, hepatocellular carcinoma; HR, hazard ratio; MVI, microvascular invasion.
Figure 3Comparison of the recurrence-free survival curves.
Notes: (A) Patients with MVI positivity combined with high KI-67 show shorter RFS compared with patients with MVI positivity combined with low KI-67. (B) Patients with MVI negativity combined with high KI-67 show no difference compared with patients with MVI negativity combined with low KI-67 in terms of RFS. (C) Patients with MVI positivity combined with high KI-67 show shorter RFS compared with patients with MVI negativity combined with high KI-67. (D) Patients with MVI positivity combined with high KI-67 show shorter RFS compared with patients with MVI negativity combined with low KI-67. (E) Patients with MVI positivity combined with low KI-67 show no difference compared with patients with MVI negativity combined with high KI-67 in terms of RFS. (F) Patients with MVI positivity combined with low KI-67 show no difference compared with patients with MVI negativity combined with low KI-67 in terms of RFS. MVI positivity/high KI-67: MVI positivity and high KI-67 positive cellular index; MVI positivity/low KI-67: MVI positivity and low KI-67 positive cellular index; MVI negativity/high KI-67: MVI negativity and high KI-67 positive cellular index; MVI negativity/low KI-67: MVI negativity and low KI-67 positive cellular index. Results are from Kaplan–Meier analysis. P<0.05 was considered to be statistically significant.
Abbreviations: MVI, microvascular invasion; RFS, recurrence-free survival.
Baseline characteristics between MVI positivity and MVI negativity groups
| Variables | MVI positivity (n=192) | MVI negativity (n=141) |
|---|---|---|
| Age (range) (years) | 48 (29–71) | 48 (29–79) |
| Sex, male/female | 162/30 | 122/19 |
| HBsAg, positive/negative | 164/28 | 124/17 |
| HBV DNA (copies/mL), >500/≤500 | 138/54 | 94/47 |
| AFP (ng/mL), >400/≤400 | 109/83 | 56/85 |
| Tumor size (cm), >5/≤5 | 139/53 | 56/85 |
| Edmondson stage, low/high | 126/66 | 97/34 |
| Node number, single/multiple | 129/63 | 106/35 |
| Capsule, incomplete/complete | 66/126 | 18/123 |
| Cirrhosis, low/high | 133/59 | 89/52 |
| KI-67 expression, high/low | 105/87 | 32/109 |
Abbreviations: AFP, alpha-fetoprotein; HBsAg, serum hepatitis B surface antigen; HBV DNA, hepatitis B virus DNA levels; MVI, microvascular invasion.
Factors associated with postoperative recurrence in HCC with MVI
| Variables | Univariate analysis
| Multivariate analysis
| |
|---|---|---|---|
| HR (95% CI) | |||
| Age >48 years | 0.105 | ||
| Sex: male | 0.541 | ||
| Positive HBsAg | 0.029 | 1.16 (0.70–1.94) | 0.60 |
| Low Edmondson stage | 0.168 | ||
| AFP >400 ng/mL | 0.025 | 1.78 (1.26–2.51) | 0.001 |
| Tumor size >5 cm | 0.662 | ||
| HBV DNA >500 copies/mL | 0.133 | ||
| Node number >1 | <0.001 | 2.13 (1.49–3.03) | <0.001 |
| Absent capsule | <0.001 | 3.03 (2.12–4.33) | <0.001 |
| Moderate or high cirrhosis | 0.114 | ||
| High KI-67 expression | <0.001 | 2.48 (1.73–3.56) | <0.001 |
| Surgical margin <1 cm | 0.342 | ||
Abbreviations: AFP, alpha-fetoprotein; HBsAg, serum hepatitis B surface antigen; HBV DNA, hepatitis B virus DNA levels; HCC, hepatocellular carcinoma; HR, hazard ratio; MVI, microvascular invasion.